Search

Your search keyword '"Serke M"' showing total 312 results

Search Constraints

Start Over You searched for: Author "Serke M" Remove constraint Author: "Serke M"
312 results on '"Serke M"'

Search Results

1. Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer

4. Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer

5. Malignes Pleuramesotheliom und maligne Pleuraergüsse

6. 1028P BIOLUMA: A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in lung cancer and to evaluate biomarkers predictive for response – results from the NSCLC cohort

8. NeoIntercal: Studienkonzept

11. BIOLUMA: A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in lung cancer and to evaluate biomarkers predictive for response - results from the NSCLC cohort

12. Corrigendum to “International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer”

13. International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer

23. PS01.04 International Tailored Chemotherapy Adjuvant Trial : ITACA Trial. Final Results

36. BIOLUMA: Biomarkers for nivolumab and evaluation of nivolumab plus ipilimumab in lung cancer

38. Durvalumab in frail and elder patients with stage four NSCLC: The DURATION trial

40. Peripheral T-cell repertoire alterations are common and affect outcome in large cell neuroendocrine lung carcinoma

42. Impact of next generation TKI and co-occurring mutations in ALK-positive NSCLC patients: Results of the Network Genomic Medicine

43. Impact of next generation tyrosine kinase inhibitors (TKI) and co-occurring mutations in ALK-positive NSCLC patients: results of the Network Genomic Medicine

44. Fibroblast kinase 1-3 inhibitor BGJ398 in patients with FGFR1 amplified squamous non-small cell lung cancer treated in a phase I study: evaluation of tumor tissue and response at a single center

45. Genetic heterogeneity of KRAS-mutated NSCLC leads to different responses to first-line platinum-based chemotherapy

46. Malignant Lymphomas and HIV Infection

47. Impact of next generation TKI and co-occurring mutations in ALK-positive NSCLC patients: Results of the Network Genomic Medicine

50. A comprehensive analysis of potentially targetable genetic aberrations and clinical findings in 821 patients with squamous-cell NSCLC - a comparison of NGM and TCGA LUSC data

Catalog

Books, media, physical & digital resources